文献速递系统性红斑狼疮

系统性红斑狼疮肺部表现的综合风险评估:一项大规模韩国人群纵向研究

Comprehensive risk assessment for pulmonary manifestations in systemic lupus erythematosus: a large-scale Korean population-based longitudinal study.
PubMed 文献 · RMD Open · 2025-02-23

这项基于韩国国民健康保险服务(2009-2017)数据的研究,纳入6074例新诊断系统性红斑狼疮(SLE)成人及按年龄性别1:10匹配的60740名对照。平均随访9.3±2.7年,SLE组肺部表现发生率为15.2/1000人年,对照组为4.5/1000人年,SLE组风险显著升高(aHR 3.26;95%CI 2.99至3.56)。

要点

  • SLE患者肺部表现风险约为匹配对照的3.3倍(aHR 3.26;95%CI 2.99至3.56)。
  • 肺动脉高压风险最高(aHR 14.66;95%CI 9.43至22.80),间质性肺病次之(aHR 9.58;95%CI 7.99至11.49)。
  • SLE组肺部表现发生率为15.2/1000人年,匹配对照组为4.5/1000人年。

核心结论

  • 与匹配对照相比,SLE患者肺部表现风险约高3.3倍(aHR 3.26;95%CI 2.99至3.56)。
  • 肺动脉高压和间质性肺病的风险尤其升高(aHR分别为14.66和9.58)。

研究设计与样本

  • 基于韩国国民健康保险服务(2009-2017)数据的人群纵向研究。
  • 纳入6074例年龄≥20岁新诊断SLE患者及按年龄和性别1:10匹配的60740名无既往肺部表现对照。

主要发现

  • 平均随访9.3±2.7年,SLE组肺部表现发生率为15.2/1000人年,匹配对照组为4.5/1000人年。
  • SLE组肺部表现风险显著升高(aHR 3.26;95%CI 2.99至3.56)。
  • 肺动脉高压aHR 14.66(95%CI 9.43至22.80),间质性肺病aHR 9.58(95%CI 7.99至11.49)。
  • 胸膜疾病aHR 3.29(95%CI 2.84至3.81),肺栓塞aHR 2.66(95%CI 2.06至3.43)。
  • 结核aHR 2.35(95%CI 1.88至2.93),急性呼吸窘迫综合征和出血aHR 1.85(95%CI 1.51至2.25),肺癌aHR 1.41(95%CI 1.02至1.95)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pulmonary involvement is common in systemic lupus erythematosus (SLE), but the relative risk of pulmonary manifestations in SLE versus non-SLE subjects remains unclear. This study aimed to evaluate the risk of pulmonary manifestations in SLE subjects compared with matched controls. METHODS: Using data from the Korean National Health Insurance Service (2009-2017), we identified 6074 individuals aged ≥20 years with newly diagnosed SLE and 60 740 matched controls by age and sex (1:10 ratio) who did not have prior pulmonary manifestations. RESULTS: Over a mean follow-up of 9.3±2.7 years, the incidence of pulmonary manifestations was 15.2 per 1000 person-years in the SLE cohort and 4.5 per 1000 person-years in the matched cohort. The SLE cohort had a significantly higher risk of pulmonary manifestations (adjusted HR (aHR) 3.26; 95% CI 2.99 to 3.56). The highest risk was observed for pulmonary hypertension (aHR 14.66; 95% CI 9.43 to 22.80), followed by interstitial lung disease (aHR 9.58; 95% CI 7.99 to 11.49), pleural disorders (aHR 3.29; 95% CI 2.84 to 3.81), pulmonary embolism (aHR 2.66; 95% CI 2.06 to 3.43), tuberculosis (aHR 2.35; 95% CI 1.88 to 2.93), acute respiratory distress syndrome and haemorrhage (aHR 1.85; 95% CI 1.51 to 2.25) and lung cancer (aHR 1.41; 95% CI 1.02 to 1.95). CONCLUSIONS: Subjects with SLE have an approximately 3.3-fold higher risk of pulmonary manifestations compared with matched controls. Notably, the risks of pulmonary hypertension and interstitial lung disease are particularly elevated.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kim BG, Kim J, Eun Y, et al. Comprehensive risk assessment for pulmonary manifestations in systemic lupus erythematosus: a large-scale Korean population-based longitudinal study. RMD Open. 2025. PMID: 39988351. doi:10.1136/rmdopen-2024-005267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。